APA (7th ed.) Citation

B, M., B, A., S, K., F, J., MK, Z., S, S., . . . A, G. (2017). Sorafenib tosylate, Ribavirn and Sofosbuvir combination therapy for HCV virus infected patients with decompensated liver cancer. Pakistan journal of pharmaceutical sciences, 30(6(Supplementary)), 2383.

Chicago Style (17th ed.) Citation

B, Munir, Ahmed B, Kiran S, Jalal F, Zahoor MK, Shehzadi S, Oranab S, Kamran SK, and Ghaffar A. "Sorafenib Tosylate, Ribavirn and Sofosbuvir Combination Therapy for HCV Virus Infected Patients with Decompensated Liver Cancer." Pakistan Journal of Pharmaceutical Sciences 30, no. 6(Supplementary) (2017): 2383.

MLA (9th ed.) Citation

B, Munir, et al. "Sorafenib Tosylate, Ribavirn and Sofosbuvir Combination Therapy for HCV Virus Infected Patients with Decompensated Liver Cancer." Pakistan Journal of Pharmaceutical Sciences, vol. 30, no. 6(Supplementary), 2017, p. 2383.